Four years after executing a $310 million deal to sell Intellikine to Takeda, biotech entrepreneur Troy Wilson is back, springing out of stealth mode with a new company that has a full team, $60 million in financing, a cancer drug in-licensed from Johnson & Johnson and a plan to start mid-stage development with two Phase II studies launching later in the year. And he's done it while working out an OTC listing that puts him in a public market with an eye to moving up to one of the national exchanges.
Takeda has been singing a globalization mantra when it comes to its vaccines unit, and that's already led it to dump one R&D program as it zeroes in on "higher impact" public health endeavors. Now, it's bowing out of another vaccine program--this time for HPV.
RNAi leaders Alnylam and Arrowhead Research are publicly disagreeing over the value of Novartis' RNAi assets. Arrowhead acquired the assets, including the rights to three preclinical candidates, for $35 million. Alnylam CEO John Maraganore said the assets were "pretty unuseful."
The French city of Marseille has staked its claim for a corner of the booming immunotherapy R&D ecosystem. And the plan has some big-name backers, with Sanofi and Innate Pharma both signing up as founders of the MI-mAbs immunotherapy research center in the city.
Houston is synonymous with oil and gas, but the inaugural class of the Texas Medical Center's TMCx accelerator attests to the city's med tech ambitions. Essentially, all of the 22 startups are in the device or health IT arena. There isn't a pure-play drug developer in the mix.
ResearchKit, Apple's new health platform, promises to transform the world's hundreds of millions of iPhones into handheld gatherers of clinical data, which some say will usher in a new era of biomedical science but could well amount to more questions than answers.
It's one of those ideas that sounds wacky and way out there, but researchers at the University of California, San Diego, have apparently found a way to draw a blood glucose sensor onto a patient's skin using regular ballpoint pen.
In typical Apple style, CEO Tim Cook announced the debut of its open-source platform for creating mobile medical apps while standing in front of a black background at a glitzy event in San Francisco. But the news contained substance too, at least from a med tech perspective.
The Association of Clinical Research Organizations (ACRO) assembled a group of CRO leaders to advise TransCelerate BioPharma, a nonprofit group run by the biggest names in drug development.
Canadian CRO conglomerate Altasciences struck a deal with preclinical researcher ITR Laboratories, joining forces to create a discovery-to-development offering for drugmakers.